Antibody-Drug Conjugates SO-N102

SOTIO’s lead candidate from its proprietary ADC platform is SO-N102, the target of which is undisclosed. 

SO-N102 has demonstrated potent anti-tumor efficacy in vitro and in vivo and, due to NBE’s proprietary site-specific sortase mediated antibody coupling (SMAC) conjugation platform, has superior manufacturing properties including stability and aggregation propensity.